Dexter D T, Carayon A, Vidailhet M, Ruberg M, Agid F, Agid Y, Lees A J, Wells F R, Jenner P, Marsden C D
Parkinson's Disease Society Research Centre, University Department of Neurology, London, England.
J Neurochem. 1990 Jul;55(1):16-20. doi: 10.1111/j.1471-4159.1990.tb08814.x.
Ferritin levels were measured in postmortem brain tissue from patients dying with Parkinson's disease [treated with L-3,4-dihydroxyphenylalanine (L-DOPA)] and from control patients. Ferritin levels were decreased in the substantia nigra, caudate-putamen, globus pallidus, cerebral cortex, and cerebellum when compared with age-matched control tissues. However, in CSF from L-DOPA-treated patients and in serum from L-DOPA-treated and untreated parkinsonian patients, ferritin levels were normal. Previous studies have suggested an increased total iron content in substantia nigra of parkinsonian brain. The failure of substantia nigra ferritin formation to be stimulated by increased iron levels suggests some defect in iron handling in this critical brain region in Parkinson's disease. The reason for decreased ferritin levels throughout the parkinsonian brain is not clear but does not seem to reflect a general system deficit in ferritin.
在死于帕金森病(接受L-3,4-二羟基苯丙氨酸(L-DOPA)治疗)的患者以及对照患者的死后脑组织中测量了铁蛋白水平。与年龄匹配的对照组织相比,黑质、尾状核-壳核、苍白球、大脑皮层和小脑中的铁蛋白水平降低。然而,在接受L-DOPA治疗的患者的脑脊液以及接受L-DOPA治疗和未治疗的帕金森病患者的血清中,铁蛋白水平正常。先前的研究表明帕金森病大脑黑质中的总铁含量增加。黑质铁蛋白形成未能因铁水平升高而受到刺激,这表明帕金森病中这个关键脑区在铁处理方面存在一些缺陷。整个帕金森病大脑中铁蛋白水平降低的原因尚不清楚,但似乎并不反映铁蛋白的一般系统缺陷。